氯吡格雷治疗急性脑梗死患者血浆GMP-140的改变与意义  

Change of Plasma GMP-140 and Clinical Effect of Clopidogrel in Treating Acute Cerebral Infarction

作　　者：朱浩佳[1] 

机构地区：[1]广东省江门市人民医院神经内科,江门529000

出　　处：《中国临床医学》2004年第4期481-482,共2页Chinese Journal of Clinical Medicine

摘　　要：目的 :观察氯吡格雷治疗急性脑梗死后患者血浆GMP - 14 0 (血小板а颗粒膜蛋白 - 14 0 )的变化并探讨其临床意义。方法 :对 6 0例起病在 2 4h的脑梗死患者随机分为治疗组和对照组 ,分别给予氯吡格雷及普通治疗 ,采用双抗体夹心酶联免疫吸附法分别测定治疗组和对照组患者治疗前后的血浆GMP - 14 0含量。结果 :治疗组患者的血浆GMP - 14 0显著低于对照组 (P<0 .0 1)。结论Objective: To investigate the change of plasma GMP-140 and clinical effect of Clopidogrel in treating acute cerebral infarction. Methods: 60 patients of cerebral infarction occurring in 24 hours were divided into treatment group and control group who were given Clopidogrel and common treatment seperately. Then assay plasma GMP-140 concent of two groups by double antibody ELISA before and after treatment. Results: Plasma GMP-140 concent of treatment group was lower than control group significantly(P<0.01). Conclusion:Clopidogrel can inhibit platelet activating.

关 键 词：氯吡格雷 治疗 急性脑梗死 血浆 GMP-140 血小板a颗粒膜蛋白-140 

分 类 号：R743.33[医药卫生—神经病学与精神病学]